title: Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients.
abstract: In this series, antilymphoid induction therapy did not appear to be necessary to prevent early graft loss from rejection. In addition, we have followed cytomegalovirus (CMV) antigenemia (pp65) for CMV infection. Although some patients developed a positive antigenemia in the seropositive to negative donor-recipient combinations, only one patient had a prolonged febrile course for 1 week.
authors.affiliation: Starzl Transplantation Institute, University of Pittsburgh, Pennsylvania, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Corry
authors.forename: M F
authors.initials: MF
authors.lastname: Egidi
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: A
authors.initials: A
authors.lastname: Sugitani
authors.forename: H A
authors.initials: HA
authors.lastname: Gritsch
authors.forename: M L
authors.initials: ML
authors.lastname: Jordan
authors.forename: S F
authors.initials: SF
authors.lastname: Dodson
authors.forename: C A
authors.initials: CA
authors.lastname: Vivas
authors.forename: V P
authors.initials: VP
authors.lastname: Scantlebury
authors.forename: A S
authors.initials: AS
authors.lastname: Rao
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D003920:Diabetes Mellitus / Q000601:surgery*; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007275:Injections, Intravenous; D016030:Kidney Transplantation; D008213:Lymphocyte Activation / Q000187:drug effects; D016035:Pancreas Transplantation; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus / Q000032:analysis*
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus